Differentiated thyroid cancer: a focus on post-operative thyroid hormone replacement and thyrotropin suppression therapy

Benjamin J. Gigliotti, Sina Jasim

Research output: Contribution to journalReview articlepeer-review

2 Scopus citations

Abstract

Purpose: This review focuses on post-operative thyroid hormone replacement and thyrotropin suppression therapy in patients with differentiated thyroid cancer. Methods: A clinical review. Results: Differentiated thyroid cancers (DTC), including papillary and follicular thyroid cancers, have an excellent prognosis and their management leverages a unique set of clinical tools arising from homology to the normal thyroid follicular cell. Surgery is the cornerstone of initial management, and post-operative care often requires thyroid hormone replacement therapy, which may be approached with the intent of physiologic normalization or used pharmacologically to suppress TSH as part of a DTC treatment. Conclusion: Management of DTC and approaches to TSH suppression are tailored to an individual’s risk of DTC recurrence and are adjusted to a patient’s clinical status and comorbidities over time with the goal of mitigating risk and maximizing benefit.

Original languageEnglish
Pages (from-to)251-258
Number of pages8
JournalEndocrine
Volume83
Issue number2
DOIs
StatePublished - Feb 2024

Keywords

  • Differentiated thyroid cancer
  • Levothyroxine
  • TSH suppression
  • Thyroid hormone replacement

Fingerprint

Dive into the research topics of 'Differentiated thyroid cancer: a focus on post-operative thyroid hormone replacement and thyrotropin suppression therapy'. Together they form a unique fingerprint.

Cite this